Overview Rapid Activity of Platelet Inhibitor Drugs Study Status: Completed Trial end date: 2013-01-01 Target enrollment: Participant gender: Summary The aim of the RAPID study is to assess the rapid onset of action of the 2 novel oral antiplatelet agents, Prasugrel and Ticagrelor, in 50 patients with STEMI undergoing PPCI with bivalirudin monotherapy. Phase: Phase 4 Details Lead Sponsor: Careggi HospitalTreatments: Platelet Aggregation InhibitorsPrasugrel HydrochlorideTicagrelor